Medicare Enrolled
Dr. Kavita Nirmal, M.D.
Hematology & Oncology · Marshall, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Nirmal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nirmal? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nirmal
Dr. Kavita Nirmal is a hematology & oncology in Marshall, TX, with 16 years in practice. Based on federal Medicare data, Dr. Nirmal performed 102,468 Medicare services across 4,656 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nirmal received a total of $1,592 from 32 pharmaceutical and/or device companies across 79 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nirmal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice▲ Top 7% volume in TX$ $1,592 industry payments
Medicare Practice Summary
Medicare Utilization ↗102,468
Medicare services
Top 7% in TX for hematology & oncology
4,656
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,404 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 29,070 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 13,195 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 11,300 | $43 | $136 |
| Contrast dye for imaging (iodine-based) | 9,506 | $0 | $3 |
| Oxaliplatin chemotherapy injection | 8,500 | $0 | $33 |
| Paclitaxel chemotherapy injection | 8,456 | $0 | $8 |
| Iron sucrose injection (Venofer) | 4,300 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 3,150 | $0 | $5 |
| Dexamethasone injection (steroid) | 1,943 | $0 | $1 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,130 | $22 | $155 |
| Blood draw (venipuncture) | 1,104 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,039 | $8 | $36 |
| Comprehensive metabolic blood panel | 988 | $10 | $64 |
| Injection, atropine sulfate, 0.01 mg | 960 | $0 | $1 |
| Office visit, established patient (20-29 min) | 629 | $58 | $250 |
| Anti-nausea injection (Aloxi/palonosetron) | 530 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 490 | $0 | $24 |
| Injection, leucovorin calcium, per 50 mg | 402 | $3 | $25 |
| Office visit, established patient (30-39 min) | 394 | $94 | $368 |
| Injection, carboplatin, 50 mg | 393 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 377 | $2 | $13 |
| Injection, irinotecan, 20 mg | 307 | $2 | $210 |
| Administration of chemotherapy into vein, 1 hour or less | 298 | $98 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 263 | $22 | $157 |
| Ferritin level test (iron stores) | 195 | $13 | $60 |
| Iron level test | 182 | $6 | $27 |
| Iron binding capacity test | 182 | $9 | $35 |
| Injection of additional new drug or substance into vein | 174 | $12 | $108 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 168 | $83 | $1,348 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 166 | $55 | $211 |
| Injection, cisplatin, powder or solution, 10 mg | 166 | $1 | $94 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 146 | $20 | $128 |
| Immunoglobulin level test | 141 | $9 | $56 |
| Administration of additional new drug or substance into vein, 1 hour or less | 133 | $48 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 111 | $47 | $313 |
| Ct scan of chest with contrast | 98 | $43 | $821 |
| Administration of chemotherapy into vein, each additional hour | 97 | $21 | $161 |
| Injection, zoledronic acid, 1 mg | 89 | $6 | $431 |
| CT scan of abdomen and pelvis with contrast | 88 | $166 | $1,067 |
| Drug injection, under skin or into muscle | 85 | $11 | $96 |
| Injection, diphenhydramine hcl, up to 50 mg | 83 | $1 | $7 |
| New patient office visit (45-59 min) | 80 | $106 | $565 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 78 | $338 | $1,722 |
| Infusion, normal saline solution , 1000 cc | 71 | $2 | $19 |
| Prothrombin time test (blood clotting) | 67 | $4 | $30 |
| Vitamin B-12 level test | 64 | $15 | $76 |
| Injection, magnesium sulfate, per 500 mg | 64 | $1 | $6 |
| Folic acid level test | 63 | $14 | $73 |
| Microscopic examination for white blood cells with manual cell count | 63 | $4 | $22 |
| Complete blood count (CBC), automated | 63 | $6 | $34 |
| Reticulated (young) platelet measurement | 62 | $35 | $143 |
| Carcinoembryonic antigen (cea) protein level | 61 | $19 | $99 |
| Unclassified drugs | 56 | $1 | $8 |
| Irrigation of implanted venous access drug delivery device | 55 | $18 | $114 |
| Thyroid stimulating hormone (TSH) test | 46 | $16 | $80 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 42 | $89 | $657 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 41 | $124 | $500 |
| Lactate dehydrogenase (enzyme) level | 39 | $6 | $31 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 37 | $1,094 | $4,802 |
| Hospital follow-up visit, high complexity | 35 | $91 | $357 |
| Administration of additional new drug or substance into vein using push technique | 34 | $42 | $289 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 31 | $15 | $94 |
| Infusion into a vein for hydration, each additional hour | 28 | $10 | $75 |
| Initial hospital admission, moderate complexity | 28 | $100 | $470 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 28 | $272 | $2,762 |
| Injection of drug or substance into vein | 26 | $28 | $247 |
| Drawing of blood for a medical problem | 26 | $72 | $264 |
| New patient office visit, complex (60-74 min) | 26 | $162 | $709 |
| CT scan of chest, without contrast | 23 | $43 | $686 |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $25 | $256 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $26 | $145 |
| Application of on-body injector for under skin injection | 14 | $14 | $96 |
| Ct scan of abdomen and pelvis without contrast | 13 | $81 | $560 |
| Hospital follow-up visit, moderate complexity | 13 | $61 | $247 |
| Flu vaccine, quadrivalent | 12 | $76 | $171 |
| Flu vaccine administration | 12 | $30 | $58 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
28.9% high complexity
65.1% medium
6.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,592
Total received (2018-2024)
Avg $318/year across 5 years
Bottom 36% in TX for hematology & oncology
32
Companies
79
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,555 (97.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$36 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$870
2023$548
2022$149
2021$12
2018$12
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$134
Merck Sharp & Dohme LLC
$132
Novartis Pharmaceuticals Corporation
$121
GlaxoSmithKline, LLC.
$116
Daiichi Sankyo Inc.
$98
Regeneron Healthcare Solutions, Inc.
$92
Tempus AI, Inc
$72
E.R. Squibb & Sons, L.L.C.
$65
Bayer Healthcare Pharmaceuticals Inc.
$59
Janssen Biotech, Inc.
$58
Seagen Inc.
$55
EMD Serono, Inc.
$53
ABBVIE INC.
$49
Eisai Inc.
$48
Lilly USA, LLC
$47
SOBI, INC
$44
Astellas Pharma US Inc
$40
Blueprint Medicines Corporation
$37
PFIZER INC.
$28
Geron Corporation
$26
Incyte Corporation
$25
Pharmacyclics LLC, An AbbVie Company
$24
Mirati Therapeutics, Inc.
$24
Stemline Therapeutics Inc.
$24
JAZZ PHARMACEUTICALS INC.
$22
CTI BioPharma Corp.
$17
Alnylam Pharmaceuticals Inc.
$17
Sun Pharmaceutical Industries Inc.
$15
Epizyme, Inc.,
$12
Seattle Genetics, Inc.
$12
Acrotech Biopharma LLC
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 24.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BAVENCIO · BELEODAQ · CALQUENCE · CARVYKTI · Doptelet · ENHERTU · Enhertu · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LUTATHERA · Lenvima · MONJUVI · OJJAARA · OPDIVO · OXLUMO · Odomzo · Orserdu · PADCEV · PLUVICTO · PROMACTA · RYTELO · SCEMBLIX · Stivarga · TAZVERIK · TECVAYLI · TUKYSA · VERZENIO · VONJO · Vonjo · XALKORI · XT CDX · Xospata · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
2
Per 100K population
2.9
County median income
$66,040
Nearest hospital
LONGVIEW REGIONAL MEDICAL CENTER
16.9 mi
16.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Nirmal is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and low-engagement industry engagement, with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Nirmal experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Nirmal performed 29,070 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nirmal receive payments from pharmaceutical companies?
Yes. Dr. Nirmal received a total of $1,592 from 32 companies across 79 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nirmal's costs compare to other hematology & oncologys in Marshall?
Dr. Nirmal's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nirmal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Marshall
Browse hematology & oncologys in Marshall ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology